Overall Survival
Results from a new study involving a genetic therapy for pleural mesothelioma have been submitted at the University of Leicester. Researchers at the United Kingdom university designed a treatment to match specific genetic profiles to individual patients. There are promising results from the study, which had patients who received first line chemotherapy combined with either…
Studies show that durvalumab and tremelimumab work very well together while treating mesothelioma. A phase I clinical trial was performed at the Baylor College of Medicine in conjunction with Baylor St. Luke’s Medical Center. Durvalumab is an immunotherapy drug known as a PD-1/PD-L1 checkpoint inhibitor. It works by blocking the connection between T-cell receptors and…
A new study is showing how the tumor microenvironment helps mesothelioma progress and survive in the body. Mesothelioma tumors create a complex microenvironment surrounding themselves. The microenvironment is simply the area surrounding the tumors. The new study shows that the microenvironment that mesothelioma tumors create assists cancer initiation and progression. Scientists are trying to figure…
Italian researchers believe that lung sparing surgery can improve survival in mesothelioma patients, even when surgeries are more conservative. Pleurectomy and decortication is the surgery that spares the lungs. It is less comprehensive than the surgery that removes the lungs, which also makes it less dangerous to patients. Doctors at the Venice-Mestre hospital have found…
An enzyme that helps clean up the byproducts of cellular oxidation could potentially be a biomarker for pleural mesothelioma. People with very small amounts of the enzyme were found to survive longer than people who have higher levels of the enzyme. The enzyme is Glutathione peroxidase-1 (GPX-1). It can be found in all cells to…
Follow-up care is crucial for treating mesothelioma patients. A study out of the United Kingdom found that when patients receive follow-up care, more input from their caregivers, continuity, and more timely information was necessary. The study involved three National Health Service facilities in England. Two of the centers were secondary care facilities while the other…
Unfortunately, there is a lack of equality when it comes to treating mesothelioma patients because access to care can be very inconsistent. Patients might not have access to a high-volume academic hospital that treats mesothelioma patients, so they are not receiving the proper care that some people might receive. Patients with mesothelioma from different areas…
Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a monoclonal antibody, which targets and restricts proteins that stimulate blood vessel growth in tumors. The Lancet Oncology published the results of the Italian study involving…
It could take time for mesothelioma patients to have better lung function after pleural mesothelioma surgery since some patients have better lung function a year after surgery compared to the days and weeks after the operation. Researchers in Japan published their findings in Integrative Cancer Therapies. There were 24 male patients with pleural mesothelioma tested…
Two immunotherapy drugs, tremelimumab and durvalumab, are showing to be a successful second line treatment for pleural mesothelioma when combined. This could mean that more treatments will be approved for the treatment of mesothelioma. The results of this phase II clinical trial were published in the Lancet Respiratory Medicine from the Department of Oncology at…
